Navigation Links
Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease

ollowing treatment.

The gene therapy procedures were performed at NewYork-Presbyterian Hospital/Weill Cornell Medical Center by Michael G. Kaplitt, M.D., Ph.D., the Tara and Victor Menezes Clinical Scholar in Neurosurgery at Weill Cornell Medical College and Director of Stereotactic and Functional Neurosurgery at NewYork-Presbyterian/Weill Cornell, and Dr. Matthew J. During, Professor of Molecular Medicine at the University of Auckland. Drs. Kaplitt and During are the co-founders of Neurologix and are consultants to the company. In a joint statement, Drs. Kaplitt and During commented: "While the primary objective of any Phase I trial is to demonstrate safety, the FDA's requirement of unilateral infusion of AAV-GAD allowed us the unique opportunity to compare treated and untreated sides of the brain. In essence, the untreated side acted as a control. The combined clinical and imaging data provide powerful evidence that this treatment appears to be efficacious, as well as safe, at the current dose levels."

This Phase I trial is the culmination of more than 10 years of basic research. In 1994, Dr. Kaplitt was the first author of a paper published in Nature Genetics, along with Dr. During as senior author, which demonstrated, for the first time in a preclinical model, that AAV could be a safe and effective vehicle for gene therapy in the brain. Most importantly, AAV has never been associated with any human disease.

According to Drs. Kaplitt and During, "The goal of this research is to determine whether we can 're-set' a specific group of cells that have become overactive, causing the characteristic impaired movements associated with Parkinson's disease. The interim UPDRS scores are highly promising and, if they are borne out with additional data, would be comparable to results seen with STN Deep Brain Stimulation. Unlike deep brain stimulation, however, our gene therapy approach is much simpler, can be carried out entirely under local an
'"/>

Source:jjackson@burnsmc.com


Page: 1 2 3 4 5 6

Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
4. GlycoFi announces the first production of antibodies with human glycosylation in yeast
5. NHGRI announces new sequencing targets
6. CHAVI announces international search for genes affecting HIV response
7. NHGRI announces latest sequencing targets
8. MUHC announces a transplant first in Quebec
9. St. Jude announces breakthrough in eye cancer treatment
10. NIH announces phase III clinical trial of creatine for Parkinsons disease
11. Insight into the processes of positive and negative learners
Post Your Comments:
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
(Date:8/4/2015)... (NASDAQ: AMRI ) today reported financial and operating results for ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... in EPS from royalties in the current quarter , ... are very pleased to present another strong financial quarter, with all ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... of researchers has found new candidate disease proteins ... of Biochemistry and Biophysics at the Perelman School ... PhD, St. Jude Children,s Research Hospital, and colleagues ... Nature that mutations in prion-like segments of ...
... study led by St. Jude Children,s Research Hospital has discovered ... nerve cells in amyotrophic lateral sclerosis (ALS), also known as ... mutation occurred in both genes and led to the abnormal ... essential role in normal RNA functioning and have also been ...
... An international group of researchers has discovered seven ... with increased risk of age-related macular degeneration (AMD), a ... network of international investigators representing 18 research groups, also ... which is published online in Nature Genetics ...
Cached Biology News:Adding to the list of disease-causing proteins in brain disorders 2Adding to the list of disease-causing proteins in brain disorders 32 new genes linked to amyotrophic lateral sclerosis and related disorders 22 new genes linked to amyotrophic lateral sclerosis and related disorders 3International consortium discovers seven new genomic regions associated with AMD 2International consortium discovers seven new genomic regions associated with AMD 3
(Date:8/31/2015)... ... August 31, 2015 , ... In recent years, biodegradable ... as low carbon footprints and compostability. These properties can help in limiting the ... the basis of applications, the market for biodegradable plastics can be broadly segmented ...
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Israel Biomedical Sensors Market - Growth, ... The Israel Biomedical Sensors market is ... of 3.73% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:8/31/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... review period following the filing of the Company,s ... the U.S. Food and Drug Administration (FDA) has ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... Israel , Aug. 31, 2015 ... Dario™ Diabetes Management Solution, today announced it recently ... million. Funds will be used to support the ... the Dario, a mobile, cloud-based, diabetes management solution ... stylish, ,all-in-one, pocket-sized, blood glucose monitoring device, and ...
Breaking Biology Technology:Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4
... New Service Helps Customers to Treat More Patients, ... ARAY ), a global leader in the ... begin offering a treatment planning,service to new and ... centers to access a dedicated team of remote ...
... Medical Specialties, a,47-physician oncology practice located in the ... into an agreement to join US Oncology,s,network. Advanced ... in the U.S., "In today,s challenging healthcare ... keep us in the strongest position to continue,delivering ...
... The National Academy of,Sciences (NAS) Council announced ... officer and executive vice president for Monsanto, has,been ... of Science. This,prize is awarded every three years ... significant, beneficial applications in,industry -- in this case, ...
Cached Biology Technology:Accuray Announces New Treatment Planning Service Offering 2Accuray Announces New Treatment Planning Service Offering 3Accuray Announces New Treatment Planning Service Offering 4Advanced Medical Specialties Joins US Oncology Network 2Advanced Medical Specialties Joins US Oncology Network 3National Academy of Sciences Recognizes Monsanto's Chief Technology Officer for Development of Agricultural Biotechnology 2
EDTA, tetrasodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99-101% (as is).Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemicals, Ul...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
...
Kit containing positive control DNA all parts of the HIV-1 genome, HIV-1 negative control DNA, Primers SK38, SK39, SK19...
Biology Products: